Current Report Filing (8-k)
April 29 2015 - 4:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 23, 2015
NUTRA PHARMA CORP.
(Exact name of registrant as specified in its charter)
| | | | |
California
| | 000-32141
| | 91-2021600
|
(State or other jurisdiction
of incorporation)
|
| (Commission File Number)
|
| (IRS Employer
Identification No.)
|
| | |
12502 West Atlantic Blvd, Coral Springs, Florida
|
| 33071
|
(Address of principal executive offices)
|
| (Zip Code)
|
Registrants telephone number, including area code: (954) 509-0911
Registrants facsimile number, including area code: (877) 895-5647
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.03
Material Modification to Rights of Security Holders
The disclosures set forth in Item 5.03 of this current report on Form 8K are incorporated by reference herein.
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On April 23, 2015, Nutra Pharma Corp., a California corporation (the Company), filed a Certificate of Amendment (the Amendment) to its Articles of Incorporation to effectuate a reverse stock split (the Reverse Split) of all the issued shares of the Companys common stock, $.001 par value per share (the Common Stock) at a ratio of one (1) share for every forty (40) shares outstanding, so that every forty (40) shares of Common Stock before the Reverse Split will represent one (1) share of Common Stock after the Reverse Split. No fractional shares will be issued, and no cash or other consideration will be paid. Instead, the Company will issue one whole share of the post-Reverse Split Common Stock to any shareholder who otherwise would have received a fractional share as a result of the Reverse Split. If approved by the Financial Industry Regulatory Authority (FINRA), the Reverse Split becomes effective with FINRA and in the marketplace at the open of business on May 18, 2015 (the Effective Date), whereupon the shares of Common Stock will begin trading on a split-adjusted basis. On the Effective Date, the Companys trading symbol will change to NPHCD for a period of 20 business days, after which the D will be removed and the Companys trading symbol will revert to the original symbol of NPHC. In connection with the Reverse Stock Split, the Companys CUSIP number will change to 67060U208.
According to the Amendment filed with the California Secretary of State, the Companys number of authorized shares of Common Stock remained unchanged at 2 billion shares. However, the Companys number of issued shares of Common Stock, whether outstanding or being held in treasury, was reduced from 1,510,950,321 to 37,773,759, and the Common Stock par value remained the same. The Reverse Split was effected after obtaining the shareholder approval required by Sections 902 and 903 of the California Corporations Code.
Each shareholders percentage ownership in the Company and proportional voting power remains unchanged after the Reverse Split, except for minor changes and adjustments resulting from the rounding of fractional interests. The rights and privileges of the holders of Common Stock are substantially unaffected by the Reverse Split.
Shareholders who are holding their shares of Common Stock in electronic form at their brokerage firms do not have to take any action as the effects of the Reverse Split will automatically be reflected in their brokerage accounts. Shareholders holding paper certificates may (but are not required to) send the certificates to the Companys transfer agent at the address given below. The transfer agent will issue a new share certificate reflecting the terms of the Reverse Split to each requesting shareholder.
Standard Registrar & Transfer Co. Inc.
12528 South 1840 East
Draper, Utah 84020
Telephone: (801) 571-8844
Fax: (801) 571-2551
Until surrender, each certificate representing shares of Common Stock before the Reverse Split would continue to be valid and would represent the adjusted number of shares of Common Stock based on the exchange ratio of the Reverse Split, rounded up to the nearest whole share. Shareholders should not destroy any stock certificate.
All options, warrants and convertible securities of the Company outstanding immediately prior to the Reverse Split will be appropriately adjusted by dividing the number of shares of Common Stock into which the options, warrants and convertible securities are exercisable or convertible by 40 and multiplying the exercise or conversion price thereof by 40, as a result of the Reverse Split.
A copy of the Amendment is attached to this current report on Form 8-K as Exhibit 3.1.
Item 9.01 Financial Statements and Exhibits
| | |
Exhibit No.
| | Exhibit Description
|
| | |
3.1
| | Certificate of Amendment to the Articles of Incorporation of Nutra Pharma Corp. as filed with the Secretary of State of the State of California on April 23, 2015.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
Date: April 29, 2015
| NUTRA PHARMA CORP.
|
| By:
| /s/ Rik Deitsch
|
| | Name:
| Rik Deitsch
|
| | Title:
| Chief Executive Officer
|
Exhibit 3.1
CERTIFICATE OF AMENDMENT
TO THE
ARTICLES OF INCORPORATION
OF
NUTRA PHARMA CORP.
The undersigned hereby certify that:
1.
They are the Chief Executive Officer and the Secretary, respectively, of NUTRA PHARMA CORP., a California corporation (the Corporation).
2.
Article FIFTH is deleted in its entirety and replaced with the following (the Amendment):
This corporation is authorized to issue two classes of stock; common and preferred. The total number of common shares which this corporation is authorized to issue is two billion (2,000,000,000) common shares, each with a par value of $.001 per share (Common Stock).
On the close of business on the date this Certificate of Amendment is filed with the California Secretary of State (the Effective Time), each forty (40) shares of Common Stock issued and outstanding or held by the Corporation in treasury stock immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof or the Corporation, be combined and converted into one (1) share of validly issued, fully paid and non-assessable Common Stock, subject to the treatment of fractional share interests as described below (the Reverse Stock Split). No fractional shares of Common Stock shall be issued in connection with the Reverse Stock Split. Rather, the fractional shares created as a result of the Reverse Stock Split shall be rounded up to the next largest whole number, such that, in lieu of fractional shares, each shareholder who otherwise would be entitled to receive fractional shares of Common Stock as a result of the Reverse Stock Split shall instead be entitled to receive the next largest whole number of shares of Common Stock.
The number of preferred shares which the corporation is authorized to issue is twenty million (20,000,000), each with a par value of $.001 per share (Preferred Stock), which Preferred Stock may be issued in one or more series as may be determined from time to time by the Board of Directors, each of which series shall be distinctly designated.
The Board of Directors is hereby authorized to fix or alter the voting rights, designations, powers, preferences and relative and other special rights, and the qualifications, limitations and restrictions of any wholly unissued series of Preferred Stock, and the number of shares of such series, and to increase or decrease the number of shares of any such series subsequent to the issue of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series of Preferred Stock shall be decreased, the shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of that series.
3.
The Amendment has been duly approved by the Board of Directors of the Corporation.
4.
The Amendment has been duly approved by the required vote of shareholders of the Corporation in accordance with Sections 902 and 903 of the California Corporations Code. The Corporation has one class of stock outstanding and such class of stock is entitled to vote on the Amendment. The total number of outstanding shares entitled to vote on the Amendment at the time that shareholder approval was obtained was 1,510,950,321 shares of Common Stock. The number of shares voting in favor of the Amendment equaled or exceeded the vote required, such required vote being more than 50% of the outstanding shares of Common Stock voting as a class.
The undersigned further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of their own personal knowledge.
IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment, effective as of this 20th day of April, 2015.
| | |
| By:
| /s/ Rik J. Deitsch
|
| Name:
| Rik J. Deitsch
|
| Title:
| President
|
| | |
| By:
| /s/ Nina Goldstein
|
| Name:
| Nina Goldstein
|
| Title:
| Secretary
|
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Apr 2023 to Apr 2024